Biocept (BIOC) Soars on Liquid Biopsy Appreciation
Post# of 135
Posted On: 02/23/2015 4:46:49 PM
The trading levels of Biocept, Inc. (BIOC) exploded in the right direction on Monday, after the company said that its blood-based diagnostic, OncoCEE-BR(TM), was used to determine hormonal status of metastatic breast cancer patients in a prospective study performed at the Columbia University College of Physicians and Surgeons in New York City.
The Columbia study used BIOC's proprietary CTC isolation platform to prospectively define hormonal status (ER/PR) using a simple blood sample in women with metastatic breast cancer. These blood samples were compared to the hormonal status results from their corresponding tumor biopsy tissue.
The study reports a high concordance of results between testing of a patient's CTCs and testing of primary and metastatic tissue. According to BIOC, the results indicate the company's blood-based diagnostic may be as effective in determining a patient's HR status as traditional tissue biopsy.
BIOC is a commercial-stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its proprietary technology platform to help improve individual patient treatment.
More about Biocept, Inc. (BIOC) at www.biocept.com
**
Shares of Rigel Pharmaceuticals, Inc. (RIGL) soared on Monday's trading session, after it reported a collaboration agreement with Bristol-Myers Squibb Company (BMY) for the discovery, development and commercialization of cancer immunotherapies based on RIGL's extensive portfolio of small molecule TGF beta receptor kinase inhibitors (TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body).
The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune system's activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors, including Bristol-Myers' Opdivo (nivolumab) and Yervoy (ipilimumab)
Under the terms of the deal, New York-based drugmaker Bristol-Myers will pay $30 million upfront and RIGL will be eligible to receive development and regulatory milestones that could total more than $309 million for a successful compound approved in multiple indications. RIGL will also be eligible to receive tiered royalties on the net sales of any products from the collaboration.
RIGL is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders.
More about Rigel Pharmaceuticals, Inc. (RIGL) at www.rigel.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of San Mateo, CA ( www.sanmateo.crwe-pr.com ) into the CRWE Network.
San Mateo, one of the largest cities in San Mateo County, California, is located approximately 20 miles south of San Francisco. Businesses in San Mateo enjoy: a highly educated employment base, close proximity to all points of the Bay Area, a traditional downtown core, regional shopping centers and access to public transit.
The City of San Mateo had an estimated population in 2013 (U.S. Census Bureau) of 101,128, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The CRWE-PR Business Directory portal ( www.BusinessDirectory.crwe-pr.com ) is the company’s business directory service that is available to all United States and Canada business in the public and private sector. It allows business owners and executives the ability to claim their business listings and provide more detailed information for their potential customers who visit the CRWE Network everyday.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
The Columbia study used BIOC's proprietary CTC isolation platform to prospectively define hormonal status (ER/PR) using a simple blood sample in women with metastatic breast cancer. These blood samples were compared to the hormonal status results from their corresponding tumor biopsy tissue.
The study reports a high concordance of results between testing of a patient's CTCs and testing of primary and metastatic tissue. According to BIOC, the results indicate the company's blood-based diagnostic may be as effective in determining a patient's HR status as traditional tissue biopsy.
BIOC is a commercial-stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its proprietary technology platform to help improve individual patient treatment.
More about Biocept, Inc. (BIOC) at www.biocept.com
**
Shares of Rigel Pharmaceuticals, Inc. (RIGL) soared on Monday's trading session, after it reported a collaboration agreement with Bristol-Myers Squibb Company (BMY) for the discovery, development and commercialization of cancer immunotherapies based on RIGL's extensive portfolio of small molecule TGF beta receptor kinase inhibitors (TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body).
The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune system's activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors, including Bristol-Myers' Opdivo (nivolumab) and Yervoy (ipilimumab)
Under the terms of the deal, New York-based drugmaker Bristol-Myers will pay $30 million upfront and RIGL will be eligible to receive development and regulatory milestones that could total more than $309 million for a successful compound approved in multiple indications. RIGL will also be eligible to receive tiered royalties on the net sales of any products from the collaboration.
RIGL is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, immuno-oncology related diseases, and muscle disorders.
More about Rigel Pharmaceuticals, Inc. (RIGL) at www.rigel.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of San Mateo, CA ( www.sanmateo.crwe-pr.com ) into the CRWE Network.
San Mateo, one of the largest cities in San Mateo County, California, is located approximately 20 miles south of San Francisco. Businesses in San Mateo enjoy: a highly educated employment base, close proximity to all points of the Bay Area, a traditional downtown core, regional shopping centers and access to public transit.
The City of San Mateo had an estimated population in 2013 (U.S. Census Bureau) of 101,128, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The CRWE-PR Business Directory portal ( www.BusinessDirectory.crwe-pr.com ) is the company’s business directory service that is available to all United States and Canada business in the public and private sector. It allows business owners and executives the ability to claim their business listings and provide more detailed information for their potential customers who visit the CRWE Network everyday.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
(0)
(0)Biocept Inc (BIOCQ) Stock Research Links
Scroll down for more posts ▼